
Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.

CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.